ABAX reported better than expected earnings
after the close Thursday. Earnings increased
across all sectors.
I suspect HSKA will also positively surprise.
Second quarter has not been good for Heska
on a seasonal basis. However, Wilson seems
to be building momentum in POC instrument
placements and radiology sales should also
Uptab, You and I have participated in ownership of several
microcaps over the years. We've done better on some than others?
Navarre, and Heska come to mind.
My question to you is?.....why do you keep making predictions
on sp of this under performing company that you admit to have
been mistaken for the last year. Anyone who owned 10,000
shares at $4.20 at the start of January has now seen 1/2 of the
share price dissipate. Why should anyone buy now and front run this
company that continues to whiplash confidence. There will be plenty
of time to buy when these jokers finally show a breath of life with a
mirror under nose. Until Hutch turns it around with numbers. It is
dead money. I say all of this, being long the outlook.
Sears.. generally, I agree. However, you have been singing
the same tune for several months as sp has dipped from $6.
You also, said the Portney's days were numbered at SIR,
and Lakewood Capital certainly didn't change the equation.
RMR seems more entrenched now that GOV has acquired SIR.
I hold this stock as a value hedge in an otherwise overvalued
market. But with all of the institutional funds that have a stake
in the static FVE. Why do you suppose none of institutional interests
have taken an activist role?
Until Wilson addresses Heska's perennial
negative operating margins, the company is
a leaky boat without a moat.
Heska can only dangle marketing incentives
for so long. The RESET program is a giveaway
of equipment hardware in lieu of a customer
agreement to buy the reagent consumables.
The business of POC testing is intensely competitive,
and commoditised. In order for Heska to grow.
The must take business from ABAX or IDXX?
If the only way HSKA can compete is to give
diagnostic equipment away. They will continue to
post negative operating margins.
I expect Wilson will positively surprise in coming
months. But it will come from growth in radiology,
and value added services. Revenue numbers will
be continue to improve in POC instruments.
But profitability will lag as long as he relies on the
RESET gimmick to place new hardware.
Both SIR and GOV are trading down today
on analyst downgrade by Wells Fargo who
deems this purchase by GOV as a ploy of
RMR to consolidate SIR into greater control
by the Portneys.
Moody's healthcare quarterly takes a look at
REITs and mentions VTR, HCP,&HCN will
continue to boost M&A in order to sustain earnings
growth. The largest Healthcare REIT's will likely
aim to acquire smaller peers. (A copy of the transcript
can be found at Ventas VTR under headlines.)
Its only a matter of time that kick the can down the road
FVE gets an unsolicted offer, or shareholder activist
backlash. This company has clearly been mismanaged
and the board should be replaced.
StarTeks diversification into the healthcare
sector gives the company unlimited upside for
growth. SRT has some of the lowest operating
margins in the business. They have literally bought
the business with the Telecoms. By diversifying
and developing other markets SRT becomes a
stronger overall competitor to their peers.
Whatever floats our boat, ahhy, Donovan?
I'm with you. Dividend should be picking up
into the last half of the year.
With Gutowski counting ore barges, and
you monitoring water levels, its all good!!!
Sentiment: Strong Buy
I agree with you on all counts. The lack of accountability
and disregard for communication invites activism of
shareholders. There is no reason for this situation to
continue. Commonwealth has shown the way.
The coming proxy allows all shareholders to voice
an opinion whether subject matter is on the ballot, or not.
When you send in your ballot, attach an addendum of
disatisfaction of the BOD, and current mgmt. Perhaps
they'll get the message.
Fundamentally, I do not know Hutch as intimately as
Uptab, longtime, and other contributors. I admit to getting
a haircut in this Minnesota based company. A year ago
I said there was no reason to front run this company whether
you believed in a turnaround, or not. Contrary to my own advice,
I averaged down with Hutch and its been the worst performer
in my crib. However, time and history past has confirmed the
good, bad, and ugly in this equity.
When you are at the bottom of the barrel, everything looks up.
When you are under the barrel its a heavy lift. We will soon
see whether this once proud company of the midwest is going
to be able to turn it around? I for one, believe there is more
to lose on the short side of this equation. GLTA.
Uptab, I don't know if you have interest in the
medical sector? APPY Venaxis is a company
with big upside potential.
The longer this undervalued gem sits as bait.
The bigger the target. RMR knows this, and SNH
does as well. The Portney's can continue to pretend
indifference. But their sphincter is tightening.
Quietly, and without fanfare Heska plods on into the second
half of the year. Seasonally, 2nd quarter results have
never been exciting.
But this year. I expect a positive surprise. The new CEO Wilson
is shaping the company to better compete with the likes of
Abaxis, and Idexx. Wilson has surplanted Grieve, and Napolitano,
as the insider with the largest share of company stock.
Wilson's bio suggests he will prep this pony for sale, like he
did in his last 2 ventures. I don't think you want to bet against
the new CEO and his team.
Heska has a checkered history of management bungling.
This CEO/ Wilson is the real deal.
There is no more ugly an equity than this stock.
It pays no dividend and is manipulated by the
principals. Shareholders can find a proxy available
at the website. But if you want to vote beyond the
pretensive bull, one needs to give Mckay and company
a personal letter in disgust of this manipulated insider
baloney. The message is clear. Why hold this proxy on
SNH without the dividend unless you want to depose the
Portnoy's and accompanying bloodsuckers.
Hold fast and voice opinion. FVE is a stinker with
the leaches attached. WE need to rid of the leaches.
Heska has been a very seasonal company
with soft summer revenues, and accompanying
swoon. Most expect Heska will do the usual wilt?
What's different? Low expectations, and a new CEO
who has been building momentum by adding new
customers. Wilson has had a track record of success
and Heska is now his baby.
If Wilson can show growth in the next earnings report,
Heska can be a $20 equity in 2015. JMO.
Floridafisherman, It sounds like you've had patience
for many years. And you give good insight to the modus
operandi of McKay & Co. Patience is the virtue of a good
fisherman. I am also long FVE and haven't received a
proxy to date? Portnoy's are not endearing themselves
to shareholders. My sense? In a market trading with rich
valuations; FVE is very undervalued, and a target for
M&A. The Ventas deal, last week, is an example.
Its only a matter of time my friend. You've already invested
6 years. You would no doubt kick yourself to cement a loss
only to find FVE in news of being acquired.
msears, I have not received a proxy, and wonder
if you have? It appears the June 6th meeting will be
adjourned and postponed until July? Any thoughts?